AstraZeneca and Cambrex, a contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), have formed a long-term manufacturing agreement under which Cambrex is supplying an intermediate. The companies made the announcement at Cambrex’s manufacturing site in Karlskoga, Sweden.

In 2017, Cambrex completed a large-scale, multi-purpose capacity expansion at the Karlskoga facility, which included the addition of hydrogenation capabilities and a continuous flow production unit capable of producing multiple metric tons of high-purity advanced intermediates per annum.  

Cambrex’s Karlskoga, site develops and manufactures small-molecule APIs, new chemical entities, and intermediates from grams to tons through all phases of the drug lifecycle. The site also features a wide range of flexible manufacturing facilities, including kilo-scale, pilot-scale, and large-scale commercial production plants. The site has more than 400 employees.

Source: Cambrex